Brief: Perspective Therapeutics Completes Recruitment For First Patient Cohort In Phase 1/2a Dose Escalation Trial Of VMT01 In Malignant Melanoma
16/10/2023 14:22
Oct 16 (Reuters) - Perspective Therapeutics Inc
CATX.A :
* PERSPECTIVE THERAPEUTICS COMPLETES RECRUITMENT FOR FIRST
PATIENT
COHORT IN PHASE 1/2A DOSE ESCALATION TRIAL OF VMT01 IN MALIGNANT
MELANOMA
Source text for Eikon: ID:nGNX4fqs4r
Further company coverage: CATX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Perspective Therapeutics
See all newsPerspective Therapeutics Q2 net loss widens on higher R&D costs
Brief: Perspective Therapeutics Q2 EPS USD -0.22
Brief: Perspective Therapeutics Expands Therapeutic Focus Areas First Patient Dosed With Vmt-Α-Net In The Meningioma Cohort Of A Phase 1/2A Study
Brief: Perspective Therapeutics Q1 EPS USD -0.25
Perspective Therapeutics rises as experimental cancer drug shows promise